11th Annual:
Reporting on the Latest Advancements and Data in IO
Immuno-Oncology 360° offered an unparalleled opportunity to hear from stakeholders representing both the science and business communities who reported on the latest data impacting IO to fight a wider range of cancers.
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/1e17f0ed8d0f55b61a375e936f3bc22900d8329f/IO 360 2024 Day 1-367.jpg)
IO360° Delivers 3 Key Benefits
1. Access to KOLs and stakeholders in the science and business communities, reporting on cutting-edge research and trends shaping IO technology, investment, and innovation
2. Presentations featuring 100+ talks on the latest innovative research delivered by international leaders from academia, investors, and industry representatives
3. 10+ hours of networking and business development opportunities to connect with 550+ attendees who specialize in cancer immunotherapy
2025 Key Topics
Biomarkers/Assay Development
Business and Investing Aspects
Discovery/Preclinical
Autoimmune Disease & IO
ADCs & IO
IO Combinations
Translational Science
Imaging Advancements
Cell Therapy
Clinical Operations
Clinical Developments
Neoadjuvant/Adjuvant Therapy
New Tech in Transformational Biology
And More
Networking and Business Opportunities
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk
Scheduled Networking:
IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
• Early evening organized historical walks of downtown Brooklyn
2025 Event Features
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/bbfd6c6b8de3534a128dee6864a15f6828ab3443/new documents created (2).png)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/8ab31938d3470f7227de10471dd29e35fff4f953/1,286.jpg)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/b2b42c6b6d5573eda4e21346959f33b4f012386d/new documents created (3).png)
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/d2313f3b0a3d925ff17ceb985d7ffe1995d450cc/new documents created (9).png)
Who Attends
![](https://d38uvx7mib76ry.cloudfront.net/public/images/d027a035850eba7f44eb24957eb004a30dd43e09/iO360 Pie Chart (1).png)
Companies Attending:
• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• BMS
• Boehringer Ingelheim
• City of Hope
• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center
• Merck
• Moderna
• Morgan Stanley
• Mount Sinai
• MPM BioImpact
• NCI
• Novartis
• OrbiMed
• RA Capital
• Regeneron
• Stanford University
• Stifel
• Takeda
• And More!
"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics
2024 Featured Speakers
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/be0777e61c9f54101e1700ec0e04a01a5b2e9bda/Rugo_Hope_New.jpeg)
Hope Rugo, MD
City of Hope
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/58ad277490941aded5d627f42ee69de35268193d/Englert_Judd.jpeg)
Judd Englert, MD, PhD
Amgen
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/37ddbd1b5fd122ba3f637abcc1ff9845dc1c429f/Chatterjee_Kishore_Moitreyee.jpeg)
Moitreyee Chatterjee-Kishore, PhD
Astellas Pharma US
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/406931d7658f16512712ecced19fba6a72a60489/lubineicki_Greg.jpeg)
Gregory Lubiniecki, MD
Merck
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/fa757dc426e2978c3dd1dd7a4425da1d41f55368/Rixe_Olivier.jpeg)
Olivier Rixe, MD, PhD
Daichii-Sankyo
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/0f3fbc32fb41969f4ce87fbfdcc0b1054d57dffc/Dolled-Fillhart_Marisa_NEW.jpg)
Marisa Dolled-Filhart, PhD
BMS
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/9041f2905e2c5628542d8b3ea670d3d501d44777/DeMario_Mark.jpeg)
Mark DeMario, MD, MPH
BioNTech US
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/969946611544d7ad1f9d505e7a7455d8f7be42ca/Perez_Edith.jpeg)
Edith Perez, MD
Bolt Therapeutics
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/7a822d29d47e9fa1fee925419a0e58229ec2f88b/Goel_Shubh.png)
Shubh Goel
AstraZeneca
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/9d33f64ec8ddf6f5df124a2562d6795718a72b3e/Meehan_Robert.jpeg)
Robert Meehan, MD
Moderna
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/126e7283f856684163f3925b7ad18a5f6a17a33b/Quezada_Sergio.jpeg)
Sergio Quezada, PhD
University College London Cancer Institute / Achilles Therapeutics
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/b93370c0638d74da4ef51d2719b918c3b86a9f7a/Singh_Harpreet.jpeg)
Harpreet Singh, PhD
Immatics
![image placeholder](https://d38uvx7mib76ry.cloudfront.net/public/images/d28f1cd74b03fd22a42cd887b4811a81b452f611/IO-360-2023-Day-1-744-(1).jpg)
Strategic Advisors